| |
| |
|
| Insider
Information: |
Deschatelets Pascal |
| Relationship: |
Chief Scientific Officer |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,115,983 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$46,101,258 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,115,983 |
|
|
| Total
Value |
$46,101,258 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -158.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Scientific Officer |
2024-05-08 |
1,115,983 |
2018-05-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
79 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• – – |
2018-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
384,292 |
945,744 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• • – |
2019-09-25 |
4 |
AS |
$25.24 |
$544,059 |
D/D |
(21,541) |
881,743 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
891,118 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• • – |
2020-02-12 |
4 |
OE |
$2.14 |
$250,821 |
D/D |
117,206 |
998,949 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• • – |
2020-02-12 |
4 |
AS |
$42.80 |
$2,228,966 |
D/D |
(52,075) |
946,874 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• • – |
2020-02-13 |
4 |
AS |
$40.98 |
$2,270,155 |
D/D |
(55,398) |
1,008,681 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• • – |
2020-02-13 |
4 |
OE |
$2.14 |
$250,819 |
D/D |
117,205 |
1,064,079 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Operating Officer |
• – – |
2020-03-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
161,656 |
847,025 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
865,775 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-02-10 |
4 |
D |
$47.72 |
$32,831 |
D/D |
(688) |
865,087 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-03-10 |
4 |
S |
$50.74 |
$317,125 |
D/D |
(6,250) |
865,087 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-03-10 |
4 |
OE |
$2.67 |
$16,688 |
D/D |
6,250 |
871,337 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-04-23 |
4 |
OE |
$2.67 |
$16,688 |
D/D |
6,250 |
871,337 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-04-23 |
4 |
AS |
$46.13 |
$288,313 |
D/D |
(6,250) |
865,087 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-04-28 |
4 |
OE |
$2.67 |
$12,015 |
D/D |
4,500 |
869,587 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-05-24 |
4 |
OE |
$2.67 |
$16,688 |
D/D |
6,250 |
875,837 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-05-24 |
4 |
AS |
$47.40 |
$296,250 |
D/D |
(6,250) |
869,587 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-06-24 |
4 |
OE |
$2.67 |
$16,688 |
D/D |
6,250 |
875,837 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2021-06-24 |
4 |
AS |
$65.61 |
$410,063 |
D/D |
(6,250) |
869,587 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
26,051 |
895,638 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-01-28 |
4 |
D |
$38.59 |
$35,927 |
D/D |
(931) |
894,707 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-02-10 |
4 |
D |
$47.12 |
$49,806 |
D/D |
(1,057) |
893,650 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-04-21 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,875) |
891,775 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-04-29 |
4 |
OE |
$2.67 |
$10,680 |
D/D |
4,000 |
895,775 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2022-04-29 |
4 |
AS |
$44.43 |
$177,720 |
D/D |
(4,000) |
891,775 |
0 |
% |
|
79 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
